Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced new employment inducement grants. The Compensation Committee of the company's Board of Directors has awarded four new employees with:

• Options to purchase a total of 27,800 shares of common stock at an exercise price of $16.31 per share
• Restricted stock units to acquire a total of 13,900 shares of common stock

These equity awards were granted under Arcus Biosciences' 2020 Inducement Plan, approved by the Board in January 2020 under the NYSE Listed Company Manual Rule 303A.08 'inducement exception'.

Arcus Biosciences (NYSE:RCUS) has secured a $250 million term loan facility from Hercules Capital, enhancing its financial position and operational flexibility. The facility includes $150 million committed, with $50 million drawn at closing and $100 million available at Arcus's discretion. This non-dilutive funding will support the recently announced Phase 3 PEAK-1 study for casdatifan, Arcus's HIF-2a inhibitor for clear cell renal cell carcinoma (ccRCC). The loan matures in five years, extendable to six, with an interest-only period of four years, extendable to five based on regulatory milestones. This financial boost allows Arcus to accelerate its development program for casdatifan across multiple ccRCC settings.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focusing on cancer therapies, has announced new employment inducement grants. The Compensation Committee of the company's Board of Directors has granted three new employees options to purchase 21,100 shares of common stock at an exercise price of $18.01 per share, which was the closing price on August 23, 2024. Additionally, restricted stock units to acquire 10,550 shares of common stock were granted. These equity awards were issued under the company's 2020 Inducement Plan, approved by the Board in January 2020 under the 'inducement exception' of NYSE Listed Company Manual Rule 303A.08.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced its participation in two upcoming investor conferences in September 2024:

• The Morgan Stanley 22nd Annual Global Healthcare Conference on September 4th at 4:55 p.m. ET in New York, NY
• The Cantor Fitzgerald Global Healthcare Conference 2024 on September 19th at 10:55 a.m. ET in New York, NY

Both events will feature fireside chats with Arcus Biosciences' management team. Live webcasts of these sessions will be available on the company's website under the 'Investors & Media' section, with replays accessible after the events.

Arcus Biosciences (NYSE:RCUS) released its Q2 2024 financial results and provided updates on its clinical pipeline. The company reported $39 million in revenue, up from $29 million YoY, and a net loss of $93 million, compared to $75 million last year. R&D expenses rose to $115 million due to late-stage programs. Arcus maintains a cash runway into 2027 with $1 billion in cash and equivalents.

Pipeline highlights include casdatifan data presentations at a medical conference in Q4 2024 and a Phase 3 study (PEAK-1) set to begin in H1 2025. The Phase 3 STAR-221 study for domvanalimab + zimberelimab with chemotherapy in upper GI cancers has completed enrollment. Additionally, the PRISM-1 Phase 3 study for quemliclustat in pancreatic cancer will start by early 2025.

Notably, Taiho Pharmaceutical has exercised its option on quemliclustat for Japan and certain Asian territories, leading to potential milestone payments to Arcus. Overall, Arcus continues to advance its pipeline with significant updates anticipated over the next 18 months.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on developing cancer therapies, has announced a conference call and webcast scheduled for August 8th, 2024, at 2 PM PT / 5 PM ET. The call will discuss the company's financial results and pipeline update for the second quarter of 2024, ending June 30th. Investors can join via phone or access the live webcast and presentation slides on the Arcus Biosciences website. A replay will be available after the event.

Arcus Biosciences (NYSE: RCUS), a clinical-stage biopharmaceutical company, announced that its Compensation Committee has granted options to six new employees to purchase a total of 25,200 shares of common stock at $13.84 per share, the closing price on July 8, 2024. Additionally, 12,600 restricted stock units were awarded. These grants were made under the company's 2020 Inducement Plan, approved by the Board of Directors as per NYSE Rule 303A.08.

Arcus Biosciences and Taiho Pharmaceutical announced that Taiho has exercised its option for an exclusive license to quemliclustat in Japan and certain other Asian territories, excluding mainland China. This action is part of a 2017 agreement, marking the fourth option Taiho has exercised in Arcus's projects. Taiho will make a payment for this option and additional payments upon reaching certain milestones. Quemliclustat is an investigational CD73 inhibitor, and Arcus plans to begin a Phase 3 trial (PRISM-1) in 2024 for treating metastatic pancreatic ductal adenocarcinoma. This decision follows promising survival data from a Phase 1b study presented at the ASCO GI Cancers Symposium. Taiho will also support and manage the PRISM-1 study in Japan.

Arcus Biosciences announces the grant of employment inducement awards to two new employees. The grants include options to purchase a total of 3,500 shares of common stock at an exercise price of $16.41 per share, the closing price on June 24, 2024, and restricted stock units for 1,750 shares. These awards are given under the 2020 Inducement Plan, approved in January 2020 under the NYSE Listed Company Manual Rule 303A.08, aimed at incentivizing new talent.